Rostab EZ Tablet 5 mg+10 mg is a combination therapy containing Rosuvastatin Calcium 5 mg and Ezetimibe 10 mg, designed for the management of hypercholesterolemia and mixed dyslipidemia in adults. This fixed-dose combination offers a dual mechanism to lower cholesterol effectively, making it suitable for patients who require enhanced lipid-lowering therapy beyond what a single agent can achieve.
Rosuvastatin, a statin, inhibits cholesterol synthesis in the liver, while Ezetimibe selectively blocks intestinal cholesterol absorption. Together, they synergistically reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides, while modestly increasing high-density lipoprotein (HDL) cholesterol. This combination is particularly valuable for patients who are at high cardiovascular risk or have familial hypercholesterolemia, offering a comprehensive approach to managing lipid disorders.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Each tablet contains:
Rosuvastatin Calcium 5 mg
Ezetimibe 10 mg
Excipients: Microcrystalline cellulose, lactose, magnesium stearate, and other standard tablet excipients
Rostab EZ Tablet 5 mg+10 mg is indicated for:
Primary hypercholesterolemia in adults to reduce LDL cholesterol and total cholesterol
Mixed dyslipidemia with elevated LDL cholesterol and triglycerides
Familial hypercholesterolemia as adjunct therapy to diet modification
Adults requiring intensive lipid-lowering therapy who are unable to achieve target cholesterol levels with statin monotherapy
Prevention of cardiovascular events such as heart attacks or strokes in high-risk patients
Rostab EZ combines two complementary mechanisms:
Rosuvastatin Calcium:
Inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver
Lowers LDL cholesterol and triglycerides while modestly increasing HDL
Stabilizes atherosclerotic plaques and improves endothelial function
Ezetimibe:
Blocks intestinal absorption of cholesterol at the brush border of the small intestine
Reduces cholesterol delivery to the liver, complementing the effect of Rosuvastatin
Provides additive LDL-lowering effect when combined with statin therapy
Together, they provide greater lipid-lowering efficacy than either drug alone, with a favorable safety profile.
Adults: 1 tablet once daily, with or without food
Swallow the tablet whole with water; do not crush or chew
Dosage may be adjusted based on lipid profile response and physician assessment
Continue dietary modifications, exercise, and weight management alongside medication for optimal results
Periodic monitoring of lipid levels, liver function tests, and kidney function is recommended
Avoid in patients with active liver disease or unexplained persistent liver enzyme elevation
Use cautiously in patients with renal impairment or history of muscle disorders
Inform the physician about all medications being taken to prevent drug interactions
Not recommended during pregnancy or breastfeeding
Seek immediate medical attention if experiencing severe muscle pain, tenderness, or weakness
Rostab EZ Tablet 5 mg+10 mg is generally well tolerated. Possible side effects include:
Headache
Mild gastrointestinal discomfort (nausea, abdominal pain)
Muscle pain or stiffness
Temporary elevation of liver enzymes
Rarely, serious muscle injury (rhabdomyolysis)
Most side effects are mild and resolve with dose adjustment or discontinuation under medical supervision.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Store below 30°C in a cool, dry place
Protect from light and moisture
Keep out of reach of children
Rostab EZ Tablet 5 mg+10 mg (Rosuvastatin + Ezetimibe) is a highly effective combination therapy for managing high cholesterol and mixed dyslipidemia. By targeting both cholesterol synthesis and absorption, it provides enhanced LDL-lowering, reduces triglycerides, and supports cardiovascular risk reduction. When combined with lifestyle interventions, Rostab EZ helps patients achieve optimal lipid control safely and conveniently.
Login Or Registerto submit your questions to seller
No none asked to seller yet